Hillsborough
Hillsborough
Hillsborough, New Jersey, United States17 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) | HIV-1 Infection | Active, not recruiting | Phase 3 | 2026-10-05 | NCT05705349 | |
| A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) | AIDS, Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Slow Virus Diseases, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Recruiting | Phase 2 / Phase 3 | 2026-09-21 | NCT07266831 | |
| A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 | HIV-1-infection | Recruiting | Phase 2 | 2026-09-04 | NCT07645287 | |
| Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients | Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 3 | 2026-08-21 | NCT02362503 | |
| Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) | AIDS, Blood-Borne Infections, DNA Virus Infections, Digestive System Diseases, Genital Diseases, HIV infectious disease, Hepadnaviridae infectious disease, Infections, RNA Virus Infections, Slow Virus Diseases, Urogenital Diseases, hepatitis, hepatitis B virus infection, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, liver disorder, sexually transmitted disease, uterine carcinosarcoma, viral hepatitis, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 2 | 2026-07-08 | NCT06497504 | |
| Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy | HIV-1-infection | Active, not recruiting | Phase 3 | 2026-06-15 | NCT06333808 | |
| Behavioral Exposure for Introceptive Tolerance RCT | Kinesiophobia, anxiety, anxiety disorder, phobic disorder, psychiatric disorder | Recruiting | Not applicable | 2026-06-12 | NCT05398276 | |
| Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 | HIV-1-Infection | Active, not recruiting | Phase 3 | 2026-05-29 | NCT06630299 | |
| Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Not stated | 2026-05-14 | NCT04136002 | |
| Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 | HIV-1-infection | Active, not recruiting | Phase 3 | 2026-04-30 | NCT06630286 | |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Chronic Disease, Digestive System Diseases, Disease Attributes, Hepatitis D, Chronic, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, hepatitis, hepatitis D virus infection, liver disorder, viral hepatitis, viral infectious disease | Active, not recruiting | Phase 3 | 2026-04-08 | NCT06903338 | |
| Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV | HIV-1 Infection | Active, not recruiting | Phase 2 | 2026-02-04 | NCT05052996 | |
| Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) | HIV-1 Infection | Active, not recruiting | Phase 3 | 2025-12-23 | NCT04776252 | |
| A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) | Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 3 | 2025-12-17 | NCT05766501 | |
| C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV | HEPATITIS C VIRUS CHRONIC INFECTION | Active, not recruiting | Phase 3 | 2025-12-05 | NCT06868264 | |
| A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051) | HIV-1 Infection | Active, not recruiting | Phase 3 | 2025-11-21 | NCT05631093 | |
| Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) | Long Term Follow-up | Recruiting | Not stated | 2024-11-27 | NCT06277037 |